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Summary:  36 
Spontaneous interferon-γ (IFNγ) released detected by enzyme-linked immunospot 37 
(ELISpot) assays may be a biological phenomenon. Markers of immune activation 38 
levels were assessed as correlates of high background among individuals in Kenya. 39 
Couples concordantly seronegative for HIV-1 were enrolled. IFN-γ ELISpot assays were 40 
conducted and negative control wells were categorized as having either high or low 41 
background (≥50 and <50 SFU/106 peripheral blood mononuclear cells (PBMC), 42 
respectively). PBMC were stained for CD4, CD8, and immune activation markers (CD38 43 
and HLA-DR) and analyzed using flow cytometry. Proportions of activated T-cells were 44 
compared between those with low and high background by Mann-Whitney U test. 45 
Correlates of background SFU and immune activation were assessed using regression 46 
models. Among 58 individuals, 14 (24%) had high background. Frequencies of 47 
CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells were higher in individuals with 48 
high background compared to those with low background (p=0.02). Higher background 49 
SFU was associated with history of sexually transmitted infections (p=0.03), and illness 50 
in the past 3 months (p=0.005), in addition to increased levels of activated CD4+ and 51 
CD8+ cells (p range=0.008-0.03). Female gender and male circumcision decreased 52 
levels of CD4+ and CD8+ immune activation (p range=0.002-0.03). Additionally, higher 53 
background SFU and activated CD4+ and CD8+ cells were individually associated with 54 
positive ELISpot responses to HIV-1 peptide pools (p range=0.01-0.03). These findings 55 
suggest that increased basal immune responses may be a biological mechanism 56 
contributing to higher background ELISpot SFU. Systematic exclusion of data from 57 
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individuals with increased background in IFN-γ release assays may bias results in 58 
population-based studies. 59 
 60 
Keywords: ELISpot; interferon gamma; IGRA, immune activation; flow cytometry, CD4, 61 
CD8, HLA-DR, CD38 62 
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Introduction:  63 
The IFN-γ enzyme-linked immunospot (ELISpot) assay is widely used to quantify 64 
viral, tumor, allo- and auto-antigenic cellular immune responses in clinical and vaccine 65 
trials. This assay is quick, cost-effective and one of the most sensitive methods to 66 
detect antigen-specific T cell responses {Schmittel, 1997 #1657;Schmittel, 2001 #235}. 67 
Quality of ELISpot assay results depends on accurate detection of spot forming units 68 
(SFU) through good staining that allows discrimination of specific spots (signal) from 69 
non-specific background spots (noise). Therefore, it is necessary to minimize 70 
background SFU in negative control wells and to maximize antigen-induced spots in 71 
experimental wells to optimize the signal-to-noise ratio. 72 
Methodological issues are commonly cited as possible reasons for spot 73 
production in negative control wells {Streeck, 2009 #1677}. Although the general 74 
consensus is that high SFU in unstimulated wells are due to assay-specific problems 75 
and should be excluded from analyses, ELISpot assays are not standardized and 76 
exclusion criteria based on high background varies depending on protocols {Streeck, 77 
2009 #1677;Cox, 2005 #1489;Immunotec, 2013 #1704}. However, biological factors 78 
may also influence basal IFN-γ production detected ex vivo. Our group has repeatedly 79 
observed dramatic differences in negative control IFN-γ responses from PBMC obtained 80 
from two individuals tested on one ELISpot plate, where the only variation in assay 81 
protocol occurred at the level of the sample. This observation propelled us to examine 82 
correlates of spontaneous IFN-γ secretion in greater detail.  83 
Studies have observed elevated immune activation among populations from 84 
developing countries compared to North American or European cohorts and 85 
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environmentally-driven factors, such as chronic infections, limited nutrition, and poor 86 
hygienic conditions, have been proposed as possible explanations for these 87 
findings{Rizzardini, 1998 #1639;Clerici, 2000 #1479;Lukwiya, 2001 #1582;Messele, 88 
1999 #1404;Borkow, 2000 #1459;Koesters, 2004 #1400}. We hypothesized that there 89 
may be a biological phenomenon mediated by increased immune activation that results 90 
in increased IFN-γ secretion ex vivo, read out as higher SFU (background) in negative 91 
controls wells of ELISpot assays. We conducted a cross-sectional study to assess the 92 
prevalence of high background among HIV-1-seronegative couples and to identify 93 
potentially modifiable biological correlates driving these background responses. 94 
 95 
Materials and Methods 96 
Study population 97 
Couples in which both partners tested HIV-1-seronegative were recruited from 98 
voluntary counseling and testing centers in Nairobi, Kenya from 2007-2009. Enrolled 99 
couples reported having sex with their partner ≥3 times in the 3 months prior to 100 
screening and did not report any outside sexual partnerships, and women participants 101 
were not pregnant. Written informed consent was obtained from all study participants, 102 
and ethical approval was received from the Institutional Review Boards at the University 103 
of Washington and Kenyatta National Hospital. Couples were seen once in clinic at 104 
enrollment. During this visit, clinical staff collected blood and genital specimens and 105 
administered questionnaires to collect sociodemographic, sexual behavior, and self 106 
reported medical history data. 107 
 108 
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Laboratory procedures 109 
Couples were determined to be concordantly HIV-1-seronegative using the 110 
Determine HIV-1/2 rapid test (Abbott, Japan) and the Bioline HIV 1/2 rapid test 111 
(Standard Diagnostics, Korea). HSV-2 serology was determined using the HerpeSelect 112 
IgG ELISA kit (Focus Technologies, USA). Equivocal HSV-2 test results were analyzed 113 
as either a negative or a positive result. Syphilis was tested using a rapid plasma reagin 114 
(RPR) test (Becton Dickinson (BD), USA); reactive tests were confirmed by T. pallidum 115 
haemagglutination assay (Randox, UK). For female participants the following tests were 116 
conducted:  urine pregnancy tests (Quick Vue One Step hCG Urine Pregnancy kit, 117 
Quidel Corporation, USA), Trichomonas vaginalis cultures (In-Pouch TV, Biomed 118 
Diagnostics, USA), and bacterial vaginosis (BV).  119 
 120 
IFN-γ ELISpot assays 121 
Blood samples from the couples were collected on the same day and batch 122 
processed to reduce introduction of within-couple variability. ELISpot assays were 123 
conducted to evaluate the frequency of background and antigen stimulated SFU with a 124 
previously described protocol using Millipore plates (Millipore, USA) and Mabtech 125 
(Mabtech, Sweden) reagents {Lohman, 2005 #1579}. One × 105 freshly isolated 126 
peripheral blood mononuclear cells (PBMC)/well were stimulated with 127 
phytohemagglutinin (PHA) (Murex Biotech Ltd, UK) in triplicate as positive control wells, 128 
media alone in 9 negative control wells, or HIV-1 peptide pools in triplicate experimental 129 
wells. Twenty-two peptide pools of 15-mers overlapping by 10 amino acids spanning the 130 
HIV-1 genome were derived from the HIV-1 subtype A consensus sequence (Sigma-131 
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Gynosys, USA). Plates were read on a CTL ImmunoSpot S4 Core Analyzer, and 132 
analyzed using ImmunoSpot Software (Cellular Technology Ltd, USA). 133 
The background response, defined as the mean SFU in the 9 negative control 134 
wells, was categorized as low (<50 SFU/106 PBMC) or high (≥50 SFU/106 PBMC). 135 
Background responses were examined both as a dichotomous (pre-defined cutoffs 136 
above) and continuous (magnitude of responses) variable. HIV-1-stimulated SFU were 137 
defined as the average number of spots in triplicate wells minus background. IFN-γ 138 
ELISpot responses were considered positive if experimental wells had ≥50 HIV-1-139 
stimulated SFU/106 PBMC and more than twice the background response. Individuals 140 
were defined as positive ELISpot responders if they had ≥1 peptide pool with a positive 141 
response.   142 
 143 
Immune activation assays 144 
Immune activation markers were measured on fresh whole blood specimens. 145 
Specimens were stained with the following pre-mixed 4-color fluorochrome-conjugated 146 
antibody combinations: anti-CD4-FITC, anti-CD38-PE, anti-CD3-PerCP, anti-HLA-DR-147 
APC and anti-CD8-FITC, anti-CD38-PE, anti-CD3-PerCP, anti-HLA-DR-APC (BD). 148 
Specimens were run on a 4-color FACSCalibur flow cytometer (BD), and flow cytometry 149 
data was analyzed and quality controlled using FlowJo software (Treestar, USA). Gates 150 
were set conservatively to capture high-level expression of CD38/HLADR. Percentages 151 
of activated cells, defined as CD38+HLA-DR+, CD38-HLA-DR+, or HLA-DR+ (CD38+ or 152 
CD38-), in both CD4+ and CD8+ subsets were used in analyses. 153 
 154 
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Statistical methods 155 
Activated cells were compared between individuals with high and low 156 
background responses and between positive and negative ELISpot responders using 157 
Mann-Whitney U tests. Linear regression with robust standard errors was used to 158 
assess correlates of background response. Data was log10 transformed when examining 159 
magnitude of background SFU as a continuous variable to achieve a normal distribution. 160 
A set of characteristics was selected a priori as potential correlates of immune activation. 161 
Both partners of the couple reported number of sex acts with their study partner in the 162 
past month, and the mean number of acts reported by the couple was used for analysis. 163 
Also, any individual who self-reported having a fever, diarrhea, vomiting or a cough in 164 
the past 3 months was considered to have a recent illness. To determine correlates of 165 
immune activation, immune activation data was modeled as a proportion, and 166 
multivariate analyses were performed for each characteristic adjusting for gender and 167 
age using generalized linear models with logit link and robust standard errors. All 168 
analyses were conducted using Stata version 11.2 statistical software (College Station, 169 
USA).  170 
 171 
Results 172 
Study population characteristics 173 
Fifty-eight individuals in monogamous, concordant HIV-1-seronegative 174 
relationships were included in the analyses. Among these individuals, 29 (50%) were 175 
females and the median age for all participants was 27 (interquartile range [IQR] 23-31) 176 
(Table 1). Median length of cohabitation was 1 year (IQR 0-7). Participants reported a 177 
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median of 4 lifetime sexual partners (IQR 3-6) and 5 sex acts (IQR 3-12) with their study 178 
partner in the past month. From self-reporting, 43 (74%) had unprotected sex in the past 179 
month, 12 (21%) had a history of sexually transmitted infections (STI), and 5 (9%) had 180 
an illness (fever, diarrhea, vomiting, or cough) in the past 3 months. Twenty (35%) 181 
individuals were HSV-2 seropositive or had an equivocal result, and 24 (83%) of the 182 
men were circumcised. Among the women, 20 (69%) used birth control, the most 183 
common form was oral, injectable or implanted hormonal contraceptives. 184 
 185 
 ELISpot background response and immune activation 186 
Of the 58 low-risk participants, the median magnitude of background response 187 
was 24 SFU/106 PBMC (IQR 10-44). Replicate spot counts per well based on input cell 188 
number of 1 × 105 cells are shown in Figure 1a, demonstrating the range of individual 189 
variability within the cohort. When ELISpot background responses were dichotomously 190 
categorized, the majority (n=44,76%) individuals had low background secretion of INF-γ, 191 
however 14 (24%) individuals were categorized as having high background with a 192 
median of 61 SFU/106 PBMC (IQR 54-121), shown in detail in Figure 1b as partners 193 
within each couple. Approximately half the individuals were in partnerships with other 194 
‘high background’ individuals, while the other half were in partnerships with individuals 195 
characterized as low background on the same plate, as shown in Figure 1c. 196 
T cells were surface stained with immune activation markers CD38+ and HLA-197 
DR+ and analyzed to determine the level of immune activation. Depending on 198 
differential CD38+ and HLA-DR+ phenotypes, 10-40% more CD8+ T cells expressed 199 
markers of activation compared to CD4+ T cells (Figure 2). When compared by ELISpot 200 
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background response, frequency of CD4+ T cells co-expressing CD38+ and HLA-DR+ 201 
was significantly elevated in individuals with high background compared to those with 202 
low background (p=0.02) (Figure 3a). Similarly, compared to individuals with low 203 
background, those with high background had higher frequencies of CD8+ HLA DR+ T 204 
cells with and without CD38 expression (p=0.02 and p=0.05, respectively) (Figure 3b). 205 
 206 
Correlates of IFN-γ ELISpot background response 207 
Univariate and multivariate models were used to evaluate the association 208 
between ELISpot background, immune activation and sociodemographic variables. 209 
ELISpot background was modeled as a continuous variable to increase the power of 210 
detecting an association and because a biologically meaningful cutoff is not known. 211 
Variables linked to infectious processes were associated with increased background. In 212 
univariate models, individuals who reported a history of STI or recent illness had higher 213 
magnitudes of log10 background SFU compared to those who did not (β=0.82, 95% 214 
confidence interval [CI]=0.07-1.56, p=0.03; β=0.98, 95% CI=0.31-1.65, p=0.005, 215 
respectively) (Table 2). There was also a trend toward higher log10 background SFU for 216 
individuals who were HSV-2 positive or equivocal (p=0.07). 217 
Furthermore, T cell activation was associated with higher magnitude of 218 
background response, similar to the previous associations when background response 219 
was examined as a dichotomous variable. Among CD4+ T cells, an increase in 220 
proportions of CD38-HLA-DR+ and total HLA-DR+ cells were associated with an 221 
increase in log10 background SFU (β=0.42, 95% CI=0.06-0.79, p=0.03; β=0.39, 95% 222 
CI=0.08-0.71, p=0.02, respectively). Analogous associations were found with higher 223 
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CD8+ T cell activation (CD38-HLA-DR+: β=0.16, 95% CI=0.04-0.28, p=0.008; HLA-DR+: 224 
β=0.13, 95% CI=0.03-0.23, p=0.01). To determine whether immune activation or 225 
infectious processes was driving the increased background responses, multivariate 226 
analyses were conducted. Infectious processes and immune activation both remained 227 
statistically significant correlates of magnitude of background SFU (range of p-values: 228 
<0.001 – 0.05), except for the model including CD4+CD38+HLA-DR+ cells.  229 
 230 
Correlates of immune activation 231 
 Having seen an association between T cell activation and IFN-γ ELISpot 232 
background response, additional analyses were conducted to examine correlates of 233 
immune activation. These analyses were adjusted for gender and age. Females were 234 
more likely to have activated CD4+CD38-HLA-DR+ (aOR=0.73, 95% CI=0.58-0.91, 235 
p=0.006) and total HLA-DR+ (aOR=0.68, 95% CI=0.52-0.87, p=0.002) compared to 236 
males (Table 3). Additionally, trends were observed indicating that women who reported 237 
any unprotected sex in the past month were more likely to have activated CD38+HLA-238 
DR+ cells (p=0.10), and those who had BV were more likely to have a higher proportion 239 
of cells expressing HLA-DR+ (p=0.09). 240 
A different set of characteristics was observed to be associated with CD8+ 241 
immune activation. Circumcised men were less likely to have activated CD38+HLA-DR+ 242 
cells (aOR=0.55, 95% CI=0.32-0.94, p=0.03). Furthermore, there were trends for 243 
females who were positive for BV to have increased proportions of total HLA-DR+ cells 244 
(p=0.07) and for those who reported hormonal contraceptive use to have decreased 245 
frequency of total HLA-DR+ cells (p=0.08).  246 
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 247 
Background and immune activation by antigen-stimulated IFN-γ ELISpot response  248 
To assess the association between immune activation and ELISpot response to 249 
antigen-specific stimulation, levels of activated cells were compared between individuals 250 
who had positive HIV-1 ELISpot results and those who had negative results. The 251 
majority (50/58, 86%) had negative IFN-γ responses to HIV-1 peptides and 9 of these 252 
50 (18%) had high background. In comparison 8 participants (14%) were categorized as 253 
positive responders and among those 63% (5/8) had a high background response. Thus, 254 
individuals with a high background response were ~7 times more likely to have a 255 
positive IFN-γ ELISpot response to HIV peptide pools (OR=7.6, p=0.01). Additionally, a 256 
strong positive correlation was seen between magnitude of background response and 257 
magnitude of HIV-1-stimulated SFU (Spearman’s =0.43, p<0.001, data not shown).  258 
Furthermore, CD38+HLADR+ expression in both CD4+ and CD8+ T cell subsets were 259 
significantly elevated in individuals who had a positive ELISpot response compared to 260 
those who did not (Figure 4). The association between presence of a positive response 261 
and magnitude of background response remained statistically significant (p≤0.05) after 262 
adjusting for frequency of CD8+HLADR+ activated cells, except when adjusting for the 263 
CD4+HLA-DR+ phenotype, which showed a trend (p=0.08, data not shown). 264 
 265 
Discussion 266 
In this study we found of high spontaneous IFN-γ release in ELISpot assays 267 
conducted on PBMC from ~25% of individuals and these individuals were more likely to 268 
have elevated levels of immune activation in both CD4+ and CD8+ T cells. Naïve T cells 269 
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differentiate into memory T cells after being activated {Hazenberg, 2000 #1530}, and 270 
the activated effector cells are then responsible for producing cytokines in vivo, most 271 
typically only during the acute immune response before the cells die or differentiate into 272 
resting memory cells. As other studies in developing countries have speculated, our 273 
participants are likely exposed to a wide spectrum of pathogens that may result in 274 
persistent infections that cause chronic immune activation. Thus, these findings support 275 
the hypothesis that highly activated T cells contribute to spontaneous IFN-γ production 276 
ex vivo detected in IFN-γ release assays.   277 
We found that a history of having a STI or an illness in the past 3 months was 278 
significantly associated with high background SFU, even after adjusting for immune 279 
activation. We expected these markers of infection to lead to an increase in activated 280 
cells, and subsequently, elevated background response; however, the immune 281 
activation markers that were measured may not have captured the whole T cell 282 
activation pathway. In addition, since unfractionated PBMC were added to our ELISpot 283 
assays, the cells of the innate immune system, particularly NK cells, may also be 284 
responsible for IFN-γ production detected in the negative control wells {Dittrich, 2012 285 
#1496}.  286 
Interestingly, different correlates were found for high background response and 287 
immune activation. Women had lower median frequencies of activated CD4+CD38-288 
HLADR+ cell phenotypes compared to men, which is consistent with a previous study 289 
that found African American women had decreased levels of the immune activation 290 
marker neopterin compared to African American men {Spencer, 2010 #1672re}. The 291 
preponderance of HLA-DR+ cells relative to CD38+ populations was unexpected. Male 292 
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circumcision was associated with decreased immune activation. Since results from 293 
large randomized clinical trials showed a strong association between male circumcision 294 
and protection against HIV-1 infection {Auvert, 2005 #1437;Bailey, 2007 #1440;Gray, 295 
2007 #1521}, it is not surprising that circumcised men have lower levels of activated T 296 
cells. Furthermore, this finding may provide an explanation as to why uncircumcised 297 
men had a higher risk for HIV-1 infection in the Step Study {McElrath, 2008 #1595}.  298 
To better understand the detection of HIV-1-stimuated responses in our HIV-1-299 
uninfected participants, we determined the effect of background SFU and immune 300 
activation on the ELISpot response. We observed higher proportions of activated T cells 301 
were associated with positive ELISpot responses. These results are similar to a 302 
previous study that showed HIV-1-negative Kenyan women who had elevated T cell 303 
immune activation expressed significantly increased IFN-γ production when stimulated 304 
with superantigen staphylococcal enterotoxin B {Koesters, 2004 #1400}. Our results 305 
suggest that either immune activation leads to non-specific IFN-γ release that may 306 
interfere with the classification of having a positive response due to background (i.e. 307 
false positives), or immune activation leads to higher levels of cross-reactivity to HIV-1 308 
peptides. Furthermore, we found that individuals with higher background SFU were 309 
more likely to have a higher magnitude HIV-1-stimulated response. When including both 310 
background response and CD8+CD38+HLA-DR+ immune activation in the model for 311 
predictors of a positive antigen stimulated ELISpot response, background remained the 312 
only statistically significant predictor. The results from adjusted models suggest 313 
activated T cells are hyper-responsive, secreting higher levels of cytokines when 314 
stimulated, and thereby producing false positive ELISpot responses mediated through 315 
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higher background responses. While these findings support the idea that activated cells 316 
may have contributed to false positive HIV-1-specific cellular responses through 317 
background response, it does not preclude the possibility of the participants being 318 
unwilling to acknowledge exposure to HIV-1 from outside partnerships, exposure that 319 
can lead to  HIV-1 specific responses{Guthrie, 2012 #1525}.   320 
Our data suggest criteria for defining positive ELISpot responses balance the risk 321 
of false positive responses with the risk of introducing significant bias through the 322 
selectively removal of data from individuals with high background. Chronic immune 323 
activation can lead to immune dysfunctions such as anergy, activation-induced cell 324 
death, cytokine dysregulation, and impaired signal transduction {Lukwiya, 2001 325 
#1582;Bentwich, 1998 #1446;Alimonti, 2003 #1431;Leng, 2002 #1576}, and previous 326 
studies have demonstrated the importance of the host’s pre-existing immune status in 327 
influencing the efficacy of immune responses to vaccine or pathogen challenge {Borkow, 328 
2002 #1458;Black, 2002 #1455}. It has been proposed that the activation state of the 329 
participants may be a possible explanation for the unexpected increase in HIV-1 330 
acquisition found in the Step study {Sekaly, 2008 #1661;McElrath, 2008 #1595}. 331 
Individuals who have elevated immune activation levels may have difficulty mounting an 332 
effective immune response, so excluding these individuals may significantly bias study 333 
findings, especially for vaccine trials.  334 
While a strength of this study was performing ELISpot assays on fresh samples 335 
to optimize sensitivity, rerunning the assays on frozen aliquots may yield different 336 
findings. Due to limited numbers of PBMC, we were not able to compare responses 337 
between fresh and frozen samples. Another limitation of this study is the limited data on 338 
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co-infections within this population. Helminth infections, malaria and TB are highly 339 
endemic in Kenya and cause a chronic immune activation state, but we were unable to 340 
diagnosis these conditions within this study.. Furthermore, unfractionated PBMC were 341 
used in the assay, and together with the use of 15-mers peptides overlapping by 10 342 
amino acids, the cell type responsible for IFN-γ secretion was not identified. While these 343 
factors may limit the scope of our conclusions, they do not affect the foundational 344 
findings. 345 
In conclusion, our results suggest that elevated levels of immune activation, 346 
along with previous infections, are associated with both higher background IFN-γ 347 
secretion and positive HIV-1 stimulated ELISpot responses in a small but significant 348 
percent of the general population. Additionally, different correlates were found to 349 
contribute to T cell activation, highlighting the intricacies of the immune response. This 350 
study indicates that conditions that lead to a persistently activated immune state in HIV-351 
1-seronegative individuals in Kenya can have a dramatic effect on immunological 352 
assays, and as such, the pre-existing immune profile of populations should be 353 
considered when developing and testing assays for measuring immunogenicity of 354 
pathogens or potential vaccines.  355 
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Figure Legends 
Figure 1. Background response of ELISpot assays among HIV-1-uninfected 
individuals. Negative control wells (replicates of 9) containing 105 PBMC and media 
only were cultured overnight for determination of background IFN-γ response. A 
reference line at 5 spots represents the cut-off number for categorizing a high (≥5 
SFU/105 PBMC) vs. low (<5 SFU/105 PBMC) response. Individual wells (squares) and 
mean ± SEM are shown per person. Individuals scoring positive for HIV peptide 
responses (>2× background and ≥ 50 spots) are indicated in red. a) Range of IFN-γ 
responses from 58 HIV-1-seronegative individuals. b) Couples in which one or both 
individuals scored as high background by IFN-γ response. c) ELISpot plate images from 
positive (columns 1-3) and negative control wells (columns 4-12) are shown for partners 
(A and B) of a couple run with the same assay conditions. Partner A was categorized as 
having a high background response and partner B as a low background response. 
 
Figure 2. Example of staining profile for immune activation markers CD38+ and 
HLA-DR+ on CD4+ and CD8+ T cells. CD38+ and HLA-DR+ staining among CD4+ and 
CD8+ T cells for an individual. Quadrants were placed conservatively high as activated 
cells generally have bright expression of these markers and this placement achieves a 
restrictive estimate of activated cells, reducing the likelihood of falsely categorizing cells 
as activated. 
 
Figure 3. Immune activation markers by ELISpot background response.  
Frequency of activated cells in (a) CD4+ T and (b) CD8+ T cell subsets are shown for 
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individuals with low (grey box plot, <50 SFU/106 PBMC) and high (open box plot, ≥50 
SFU/106 PBMC) background response. Upper, middle, and lower lines of the box show 
group 75th percentile, median, and 25th percentile, respectively, individual outliers 
indicated by solid circles. P-values compare the distribution of the percent of activated 
cells for individuals with low background to those with high background, based on the 
Mann-Whitney U test.   
 
Figure 4. Immune activation markers by ELISpot response. Frequency of activated 
cells in (a) CD4+ T and (b) CD8+ T cell subsets are shown for individuals with negative 
(filled box) and positive (open box) ELISpot response, defined as 2-fold over 
background and at least 50 SFU/106 cells. Upper, middle, and lower lines of the box 
show group 75th percentile, median, and 25th percentile, respectively. P-values compare 
the distribution of the percent of activated cells for individuals with negative response to 
those with positive response, based on the Mann-Whitney U test 
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Table 1. Cohort characteristics of concordant HIV-1-seronegative couples. 
Characteristic 
Median (IQR) or n (%) 
(N=58)* 
Female 29 (50) 
Age 27 (23 - 31) 
Years living together 1 (0 - 7) 
Lifetime sexual partners 4 (3 - 6) 
Sex acts a 5 (3 -12) 
Any unprotected sex a 43 (74) 
History of STI 12 (21) 
HSV-2 serostatus   
Negative 37 (65) 
Equivocal 5 (9) 
Positive 15 (26) 
Bacterial vaginosis 5 (31) 
Recent illness b 5 (9) 
Male circumcision 24 (83) 
Birth control use 20 (69) 
Hormonal birth control use c 13 (45) 
  IQR, interquartile range; STI, sexually transmitted infection 
* N=29 for characteristics unique to men or women. Bacterial vaginosis results were 
available for 16 women. 
a With study partner in the past month  
b Reported fever, diarrhea, vomiting, or cough in the past 3 months  
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Table 2. Correlates of magnitude of ELISpot background responses. 
Characteristic (N=58)* Coeff 95% CI p-
value 
Univariate Analyses a    
Female -0.03 -0.68 – 0.61 0.92 
Age (per 5 years) 0.03 -0.14 – 0.20 0.73 
Years living together -0.03 -0.18 – 0.11 0.64 
High sexual partners b 0.22 -0.42 – 0.87 0.49 
Sex acts c -0.001 -0.05 – 0.05 0.97 
Any unprotected sex c 0.54 -0.19 – 1.27 0.15 
History of STI 0.82 0.07 – 1.56 0.03 
HSV-2 seropositive (positive or 
equivocal) d 
0.60 -0.05 – 1.25 0.07 
Bacterial vaginosis -0.31 -1.45 – 0.83 0.57 
Recent illness e 0.98 0.31 – 1.65 0.005 
Male circumcision -0.35 -1.27 – 0.56 0.43 
Hormonal birth control use f -0.58 -1.51 – 0.36 0.22 
CD4+CD38+HLA-DR+ 0.76 -0.44 – 1.96 0.21 
CD4+CD38-HLA-DR+ 0.42 0.06 – 0.79 0.03 
CD4+HLA-DR+ 0.39 0.08 – 0.71 0.02 
CD8+CD38+HLA-DR+ 0.23 -0.05 – 0.51 0.10 
CD8+CD38-HLA-DR+ 0.16 0.04 – 0.28 0.008 
CD8+HLA-DR+ 0.13 0.03 – 0.23 0.01 
    
Multivariate Analyses g    
History of STI 0.70 0.07 – 1.33 0.03 
Recent illness 0.95 0.51 – 1.39 <0.001 
CD4+CD38+HLA-DR+ 0.82 -0.28 – 1.92 0.14 
    
Recent illness 0.92 0.37 – 1.46 0.001 
CD4+CD38-HLA-DR+ 0.40 0.05 – 0.75 0.03 
    
Recent illness 0.96 0.45 – 1.48 <0.001 
CD4+HLA-DR+ 0.39 0.08 – 0.69 0.01 
    
History of STI 0.73 0.06 – 1.40 0.03 
Recent illness 0.95 0.48 – 1.42 <0.001 
CD8+CD38+HLA-DR+ 0.27 0.00 – 0.53 0.05 
    
History of STI 0.67 0.02 – 1.32 0.04 
Recent illness 0.91 0.48 – 1.34 <0.001 
CD8+CD38-HLA-DR+ 0.17 0.05 – 0.28 0.004 
    
History of STI 0.68 0.05 – 1.32 0.04 
Recent illness 0.95 0.52 – 1.39 <0.001 
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CD8+HLA-DR+ 0.13 0.04 – 0.23 0.005 
 
Coeff = beta coefficient from regression model; CI = confidence interval; STI = sexually 
transmitted infections 
* N=29 for characteristics unique to men or women. Bacterial vaginosis results were 
available for 16 women. 
a Association between log10 background SFU and each covariate is examined 
separately in unadjusted models 
b Lifetime sexual partners dichotomized at median: <4 and ≥4 
c With study partner in the past month  
d HSV-2 seropositive defined as positive or equivocal HSV-2 test results  
e Reported fever, diarrhea, vomiting, or cough in the past 3 months  
f Hormonal birth control use defined as oral contraceptives, injectables, or implants 
g Multivariate analyses included history of STI, recent illness, and immune activation as 
covariates; models with CD4+C38-HLA-DR+ and CD4+HLA-DR+ cells only included 
recent illness due to co-linearity with history of STI 
BOLD indicates p≤0.05 
 
 
